PCSK9 inhibition with a novel fusion protein VICTORION-INITIATE supports early inclisiran treatment in ASCVD LIBerate-HR: Lerodalcibep reduces LDL-C in high and very high risk CVD US patients missing out on bempedoic acid Evolocumab benefits in patients with autoimmune and inflammatory diseases CLEAR Outcomes confirms bempedoic acid benefits for recurrent CV events

Professor Patrice Therond

Head of Biochemistry Department

Head of Biochemistry Department
Bicêtre University Hospital, AP-HP, Paris-Saclay University, France

University professor of biochemistry and hospital practitioner (PUPH), University Paris-Saclay.

Expertise in genetic diagnosis of hereditary metabolic diseases and biological monitoring of dyslipidemic patients.

Research activities:
Statin action on the composition of LDL and HDL subclasses and LDL-derived phospholipid hydroperoxides in atherogenic dyslipidemia.

Mitochondrial dysfunctions and regulation of oxidative stress in foam cells.

« Back to Editorial Board

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters

Professor Patrice Therond

Find out more

About PCSK9 Education and Research Forum

Editorial Policy